OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands

Disclosure: M.R. Gadelha: Advisory Board Member; Self; Crinetics Pharmaceuticals, Ipsen, Novo Nordisk, and Recordati Rare Diseases. Research Investigator; Self; Crinetics Pharmaceuticals and Recordati Rare Diseases. Speaker; Self; Crinetics Pharmaceuticals, Ipsen, Novo Nordisk, and Recordati Rare Di...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadelha, Monica R, Randeva, Harpal Singh, Gordon, Murray B, Doknic, Mirjana, Mezosi, Emese, Toth, Miklos, Boguszewski, Cesar Luiz, Ferrara-Cook, Christine T, Casagrande, Alessandra, Krasner, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology And Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554043/
http://dx.doi.org/10.1210/jendso/bvad114.1083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554043/
http://dx.doi.org/10.1210/jendso/bvad114.1083

Ejemplares similares